TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25592008

Group type: EXPERIMENTAL
Intervention: Lactoferrin-fortified formula (38 mg/100 g milk, iron 4 mg/100 g milk)
Number of subjects: 260

Group type: COMPARATOR
Intervention: Control group (no lactoferrin, iron 4 mg/100 g milk)
Number of subjects: 260
Study: 23219989

Group type: EXPERIMENTAL
Intervention: Television viewing
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Being alone
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Driving
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Social interaction
Number of subjects: 81
Study: 21424914

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Rosiglitazone
Number of subjects: 40
Study: 18291276

Group type: EXPERIMENTAL
Intervention: Enamel matrix derivative (EMD)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Formocresol (FC)
Number of subjects: 15
Study: 16784916

Group type: EXPERIMENTAL
Intervention: Presence of collaterals (Rentrop grade >1)
Number of subjects: 561

Group type: EXPERIMENTAL
Intervention: Independent determinants of collaterals
Number of subjects: 561
Study: 12698851

Group type: EXPERIMENTAL
Intervention: Neoselenium (immunorehabilitation)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Broncholytics (basic treatment)
Number of subjects: 55
Study: 10952795

Group type: EXPERIMENTAL
Intervention: Three-Compartment Bags (TCB)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Separate Bottles (SB)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Hospital‐Compounded Bags (HCB)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: All systems (SB, HCB, TCB)
Number of subjects: 60
Study: 9192122

Group type: EXPERIMENTAL
Intervention: Step height of 6 inches
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Step height of 8 inches
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Step height of 10 inches
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control group (not explicitly defined)
Number of subjects: 12
Study: 1372723

Group type: EXPERIMENTAL
Intervention: Pacing rate increased to 100 beats/min
Number of subjects: 15

Group type: COMPARATOR
Intervention: Pacing rate remained at 70 beats/min
Number of subjects: 15

Group type: COMPARATOR
Intervention: Pacing rate at 70 beats/min
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Pacing rate at 100 beats/min
Number of subjects: 15
Study: 3887964

Group type: EXPERIMENTAL
Intervention: Alprazolam
Number of subjects: 100

Group type: COMPARATOR
Intervention: Chlordiazepoxide
Number of subjects: 100
Study: 30763468

Group type: EXPERIMENTAL
Intervention: Pulsed Signal Therapy (PST)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 25
Study: 29365083

Group type: EXPERIMENTAL
Intervention: Immediate etoposide (ET) with ART (up to 8 cycles)
Number of subjects: 190

Group type: COMPARATOR
Intervention: As-needed etoposide (ET) with ART
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: Immediate etoposide (ET)
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: Both arms
Number of subjects: 190
Study: 27203797

Group type: EXPERIMENTAL
Intervention: Nonsteroidal anti-inflammatory drugs (NSAIDs)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Opioids
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: N-methyl D-aspartate (NMDA) receptor antagonists
Number of subjects: 0

Group type: COMPARATOR
Intervention: NSAIDs
Number of subjects: 0

Group type: COMPARATOR
Intervention: Local anaesthetics
Number of subjects: 0
Study: 24721107

Group type: EXPERIMENTAL
Intervention: One-operator technique
Number of subjects: 352

Group type: COMPARATOR
Intervention: Two-operator technique
Number of subjects: 352
Study: 22266741

Group type: EXPERIMENTAL
Intervention: 10 mL of 0.5% bupivacaine
Number of subjects: 98

Group type: COMPARATOR
Intervention: 3 mL of hyaluronic acid (HA)
Number of subjects: 98
Study: 20720101

Group type: EXPERIMENTAL
Intervention: Intervention participants (dietary counseling and training on portion-size estimation)
Number of subjects: 3088

Group type: COMPARATOR
Intervention: Nonintervention participants
Number of subjects: 3088

Group type: EXPERIMENTAL
Intervention: Intervention participants
Number of subjects: 3088
Study: 17657474

Group type: EXPERIMENTAL
Intervention: GAD65 autoantibodies (GADAs)
Number of subjects: 242
Study: 16000279

Group type: EXPERIMENTAL
Intervention: Automated evaluation of DAT binding ratios using a standardized 3-dimensional volume-of-interest (VOI) map
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Manual evaluation of DAT binding ratios
Number of subjects: 155

Group type: COMPARATOR
Intervention: Visual findings
Number of subjects: 155
Study: 12378360

Group type: EXPERIMENTAL
Intervention: Use of arterial tourniquet with pressure of 350 mmHg (group A)
Number of subjects: 80

Group type: COMPARATOR
Intervention: No tourniquet used (group B)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 80
Study: 10332444

Group type: EXPERIMENTAL
Intervention: Trazodone 50 mg at bedtime
Number of subjects: 51
Study: 8726616

Group type: EXPERIMENTAL
Intervention: Sclerotherapy using 1% hydroxypolyaetoxydodecan (polidocanol)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Surgery alone (control group)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Sclerotherapy
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Sclerotherapy and Surgery (both groups)
Number of subjects: 20
Study: 1914952

Group type: EXPERIMENTAL
Intervention: Biofeedback (BF)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Acupuncture (AP)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Cinnarizine (Cin)
Number of subjects: 58
Study: 7008212

Group type: EXPERIMENTAL
Intervention: Crithidia luciliae test
Number of subjects: 93

Group type: COMPARATOR
Intervention: Radioimmunoassay technique
Number of subjects: 93
Study: 31785536

Group type: EXPERIMENTAL
Intervention: Any alcohol use
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Unhealthy alcohol use (UAU)
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Heavy episodic drinking (HED)
Number of subjects: 220
Study: 30993684

Group type: EXPERIMENTAL
Intervention: Treatment group (n = 29) received two 75-min lessons on evaluating the credibility of online content.
Number of subjects: 67

Group type: COMPARATOR
Intervention: Control group (n = 38) did not receive the intervention.
Number of subjects: 67
Study: 29178711

Group type: EXPERIMENTAL
Intervention: Fluoride toothpaste plus 3% KNO3 mouthwash
Number of subjects: 216

Group type: COMPARATOR
Intervention: Fluoride toothpaste alone
Number of subjects: 216
Study: 26547062

Group type: EXPERIMENTAL
Intervention: Text-messaging smoking cessation intervention
Number of subjects: 197

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 197
Study: 25100444

Group type: EXPERIMENTAL
Intervention: Normal moves (full video clips)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Deceptive moves
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Point-light clips (normal turns)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Point-light clips (deceptive turns)
Number of subjects: 0
Study: 21929528

Group type: EXPERIMENTAL
Intervention: EPO (800 IU/kg intravenously)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 50
Study: 19429518

Group type: EXPERIMENTAL
Intervention: Selective strapping of the rib cage
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Selective strapping of the abdomen
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Total chest wall strapping
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control conditions (no strapping)
Number of subjects: 10
Study: 17235334

Group type: EXPERIMENTAL
Intervention: rosiglitazone 8 mg/day for 6 months
Number of subjects: 37

Group type: COMPARATOR
Intervention: placebo for 6 months
Number of subjects: 37
Study: 14768919

Group type: EXPERIMENTAL
Intervention: Remifentanil (1 microg kg(‐1) bolus then 0.1‐0.5 microg kg(‐1) min‐1)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Alfentanil (30 microg kg(‐1) bolus then 0.16‐0.83 microg kg(‐1) min‐1)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Remifentanil
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Alfentanil
Number of subjects: 98

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 98
Study: 12480424

Group type: EXPERIMENTAL
Intervention: Single-dose azithromycin (20 mg/kg bodyweight, maximum individual dose 1 g; n=65)
Number of subjects: 128

Group type: COMPARATOR
Intervention: 12.5 mg/kg erythromycin (maximum dose 500 mg; n=63)
Number of subjects: 128
Study: 9620115

Group type: EXPERIMENTAL
Intervention: Intramuscular injection of a standard trivalent influenza vaccine
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Subcutaneous injection of a standard trivalent influenza vaccine
Number of subjects: 26
Study: 8590521

Group type: EXPERIMENTAL
Intervention: Esophageal dilatation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Proton pump inhibitors
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pneumatic dilatation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Botulinum toxin injection
Number of subjects: 0

Group type: COMPARATOR
Intervention: Blind passage, fluoroscopic guidance, endoscopically directed dilatation
Number of subjects: 0
Study: 2295775

Group type: EXPERIMENTAL
Intervention: Walk/jog (n = 17)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Strength training (n = 20)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Control group (n = 12)
Number of subjects: 49
Study: 347112

Group type: EXPERIMENTAL
Intervention: deanol acetamidobenzoate, 2.0 g/day for four weeks
Number of subjects: 14

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 14
Study: 30367462

Group type: EXPERIMENTAL
Intervention: Secukinumab 300 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Secukinumab 150 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 28069021

Group type: EXPERIMENTAL
Intervention: EXPECT (psychological pre-surgery intervention to optimize outcome expectations)
Number of subjects: 124

Group type: COMPARATOR
Intervention: SUPPORT (psychological control intervention focusing on emotional support)
Number of subjects: 124

Group type: COMPARATOR
Intervention: SMC (standard medical care)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: EXPECT
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: EXPECT and SUPPORT
Number of subjects: 124
Study: 25932600

Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 112

Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 112
Study: 23460409

Group type: EXPERIMENTAL
Intervention: Laryngeal Tube (LT) size 2
Number of subjects: 40

Group type: COMPARATOR
Intervention: Laryngeal Mask Airway (LMA) size 2
Number of subjects: 40
Study: 21711059

Group type: EXPERIMENTAL
Intervention: Fostamatinib 100 mg twice daily
Number of subjects: 875

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 875
Study: 19139013

Group type: EXPERIMENTAL
Intervention: Combined 13‐cis‐retinoic acid daily, alpha‐IFN twice weekly, and alpha‐tocopherol daily for 1 year
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Maintenance fenretinide
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: CD1 AA/AG genotype
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: High CD1 expression
Number of subjects: 27
Study: 17337141

Group type: EXPERIMENTAL
Intervention: Diflunisal 500 mg
Number of subjects: 121

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 121
Study: 15325237

Group type: EXPERIMENTAL
Intervention: Natural compounds collected from lactating women and their breastfeeding infants
Number of subjects: 0
Study: 11397028

Group type: EXPERIMENTAL
Intervention: Single ultrasonic scan at age 65
Number of subjects: 6058

Group type: EXPERIMENTAL
Intervention: Screened group (including refusers)
Number of subjects: 6058

Group type: EXPERIMENTAL
Intervention: Screened group
Number of subjects: 6058

Group type: EXPERIMENTAL
Intervention: Uncontrolled sample offered a scan at age 65
Number of subjects: 6058

Group type: EXPERIMENTAL
Intervention: Initially normal aortic diameter
Number of subjects: 6058
Study: 9425670

Group type: EXPERIMENTAL
Intervention: Single judgment task for spatial frequency or contrast
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dual discrimination of contrast and spatial frequency
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dual discrimination of 2 contrast or spatial frequency components
Number of subjects: 0

Group type: COMPARATOR
Intervention: Relative spatial location of components
Number of subjects: 0
Study: 8438775

Group type: EXPERIMENTAL
Intervention: Beta-carotene (20 mg/d)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study: 3098825

Group type: EXPERIMENTAL
Intervention: Intramuscular route of FSH administration
Number of subjects: 12

Group type: COMPARATOR
Intervention: Pulsatile subcutaneous route of FSH administration
Number of subjects: 12
Study: 29189279

Group type: EXPERIMENTAL
Intervention: Alkalinized lidocaine (group AL)
Number of subjects: 213

Group type: COMPARATOR
Intervention: Saline (group S)
Number of subjects: 213
Study: 26540368

Group type: EXPERIMENTAL
Intervention: Patellar resurfacing
Number of subjects: 115

Group type: COMPARATOR
Intervention: No patellar resurfacing (Control)
Number of subjects: 115
Study: 25329386

Group type: EXPERIMENTAL
Intervention: Educational small groups meetings led by pharmacists (TEA trial)
Number of subjects: 1737

Group type: EXPERIMENTAL
Intervention: Educational small groups meetings led by pharmacists (SIDRO trial)
Number of subjects: 1737
Study: 23558840

Group type: EXPERIMENTAL
Intervention: Dexamethasone (IV 8 mg)
Number of subjects: 185

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 185
Study: 20615884

Group type: EXPERIMENTAL
Intervention: Pooled HPV genotype test (hybrid capture 2; hc2)
Number of subjects: 671

Group type: COMPARATOR
Intervention: Research PCR HPV genotyping test (line blot assay; LBA)
Number of subjects: 671

Group type: EXPERIMENTAL
Intervention: Persistent HPV16 among women repeatedly hc2+
Number of subjects: 671
Study: 18793930

Group type: EXPERIMENTAL
Intervention: F-file
Number of subjects: 60

Group type: COMPARATOR
Intervention: Ultrasonically activated #20 K-file
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Ultrasonically activated #20 K-file with EDTA
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: F-file with EDTA
Number of subjects: 60
Study: 12114338

Group type: EXPERIMENTAL
Intervention: Tiotropium 18 microg once daily via dry-powder inhaler
Number of subjects: 623

Group type: EXPERIMENTAL
Intervention: Salmeterol 50 microg bid via metered-dose inhaler
Number of subjects: 623

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 623
Study: 9424040

Group type: EXPERIMENTAL
Intervention: Case management intervention
Number of subjects: 419

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 419

Group type: EXPERIMENTAL
Intervention: Case management intervention (for those with 3 or fewer well-child visits)
Number of subjects: 419

Group type: EXPERIMENTAL
Intervention: Case management intervention (for the 25% with inadequate preventive health visits)
Number of subjects: 419
Study: 8586119

Group type: EXPERIMENTAL
Intervention: 1.5 ppm NO2 for 20 min (Group A)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 3.5 ppm NO2 for 20 min (Group B)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 3.5 ppm NO2 for 4 h (Group C)
Number of subjects: 24
Study: 2671369

Group type: EXPERIMENTAL
Intervention: Health education programme on salt reduction
Number of subjects: 800

Group type: COMPARATOR
Intervention: Control community (no intervention)
Number of subjects: 800
Study: 782144

Group type: EXPERIMENTAL
Intervention: Propranolol (Inderal) 160 mg/d
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Propranolol (Inderal)
Number of subjects: 22
Study: 31512187

Group type: EXPERIMENTAL
Intervention: Telemonitoring with team-based management
Number of subjects: 240

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 240
Study: 31037755

Group type: EXPERIMENTAL
Intervention: six-session face-to-face individual intervention
Number of subjects: 154

Group type: COMPARATOR
Intervention: control group
Number of subjects: 154
Study: 28034981

Group type: EXPERIMENTAL
Intervention: Intravenous acetaminophen (IVA) 1000 mg
Number of subjects: 67

Group type: COMPARATOR
Intervention: Oral acetaminophen (OA) 1000 mg
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Both IVA and OA
Number of subjects: 67
Study: 26426451

Group type: EXPERIMENTAL
Intervention: Attention modification (AMC)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Attend-to-geometrics (AGC)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Attention control (ACC)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 68
Study: 22883130

Group type: EXPERIMENTAL
Intervention: Thoracic spinal manipulative therapy (SMT)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Sham-SMT
Number of subjects: 69

Group type: COMPARATOR
Intervention: Sham-ultrasound
Number of subjects: 69
Study: 22286593

Group type: EXPERIMENTAL
Intervention: Integrative psychotherapeutic programme (IRR)
Number of subjects: 168

Group type: COMPARATOR
Intervention: Usual nursing home care
Number of subjects: 168
Study: 18719060

Group type: EXPERIMENTAL
Intervention: Preoperative smoking cessation intervention (PISC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not subjected to PISC)
Number of subjects: 0
Study: 17113139

Group type: EXPERIMENTAL
Intervention: Three-step etch-and-rinse adhesive systems (Allbond 2, Clearfil LB, Denthesive)
Number of subjects: 337

Group type: EXPERIMENTAL
Intervention: Two-step etch-and-rinse adhesive system (Gluma 2000)
Number of subjects: 337

Group type: EXPERIMENTAL
Intervention: Self-etch adhesive systems (ART, Denthesive 2, PUB 3)
Number of subjects: 337

Group type: EXPERIMENTAL
Intervention: Overall retention of all adhesive systems
Number of subjects: 337

Group type: EXPERIMENTAL
Intervention: ADA acceptance criteria
Number of subjects: 337
Study: 16871741

Group type: EXPERIMENTAL
Intervention: Haemodialysis with glucose-containing fluid
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Haemodialysis with glucose-free fluid
Number of subjects: 123

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 123
Study: 11313230

Group type: EXPERIMENTAL
Intervention: Health education campaigns in target villages
Number of subjects: 577

Group type: COMPARATOR
Intervention: Control group (no education campaign)
Number of subjects: 577
Study: 9387175

Group type: EXPERIMENTAL
Intervention: 50 burns to half of the trabecular meshwork
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: 35 burns to one third of the trabecular meshwork
Number of subjects: 122
Study: 8197033

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 500 mg every 12 hours (C500)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 750 mg every 12 hours (C750)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Nalidixic acid 1 g every 6 hours (NA)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 2884813

Group type: EXPERIMENTAL
Intervention: guanfacine 1-2 mg
Number of subjects: 13

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 13
Study: 31202690

Group type: EXPERIMENTAL
Intervention: Ritonavir-boosted darunavir 400 mg once daily
Number of subjects: 300

Group type: COMPARATOR
Intervention: Ritonavir-boosted lopinavir 800 mg plus 200 mg ritonavir
Number of subjects: 300
Study: 27883220

Group type: EXPERIMENTAL
Intervention: Zingiber officinale-based lip plumper
Number of subjects: 60
Study: 24928790

Group type: EXPERIMENTAL
Intervention: FP‐01.1 (150 μg/peptide dose group)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study: 23705536

Group type: EXPERIMENTAL
Intervention: Daily patient-applied subgingival root brushing for 14 days
Number of subjects: 11

Group type: COMPARATOR
Intervention: Pre-existing tooth brushing and flossing regimen (Control)
Number of subjects: 11
Study: 22256633

Group type: EXPERIMENTAL
Intervention: Moxibustion treatment (3 cones on each point, applied to Neixiyan, Dubi, and Ashi points, once every two days, 3 times per week for 6 weeks)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Placebo moxibustion treatment (placebo moxa sticker applied to the same points)
Number of subjects: 59
Study: 19822595

Group type: EXPERIMENTAL
Intervention: High-dose cysteine (81 mg/kg per day)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Standard dose cysteine (45 mg/kg per day)
Number of subjects: 20
Study: 16477445

Group type: EXPERIMENTAL
Intervention: 6 months of supervised sprint training program (3 days/week)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Normal activity (control group)
Number of subjects: 12
Study: 15243608

Group type: EXPERIMENTAL
Intervention: Lower stabilising splint (SS)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Non-occluding control (CS)
Number of subjects: 93
Study: 11552140

Group type: EXPERIMENTAL
Intervention: Fibrin adhesive
Number of subjects: 26

Group type: COMPARATOR
Intervention: Resorbable oxycellulose dressing
Number of subjects: 26
Study: 9644774

Group type: EXPERIMENTAL
Intervention: Continuous sequential regimen of 5 micrograms/day of estradiol and 5 mg/day of medrogestone from the 17th to the 28th day of the cycle (Group A)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Continuous administration of 50 micrograms/day estradiol and 5 mg/day medrogestone (Group B)
Number of subjects: 80
Study: 8187428

Group type: EXPERIMENTAL
Intervention: 40, 80, 120, 160 or 200 mg rimexolone (Org 6216)
Number of subjects: 20
Study: 3556307

Group type: EXPERIMENTAL
Intervention: Irradiation therapy
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Combined chemo‐irradiation therapy (Adriamycin/Cyclophosphamide)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Combined irradiation-polychemotherapy (Adriamycin/Cyclophosphamide or Adriamycin/Cisplatin)
Number of subjects: 124

Group type: COMPARATOR
Intervention: No therapy
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Combined polychemotherapy including Cisplatin
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Adjuvant therapy
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Stage I tumors
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Stage II tumors
Number of subjects: 124
Study: 29205286

Group type: EXPERIMENTAL
Intervention: Anamorelin (100 mg daily for 12 weeks)
Number of subjects: 174

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 174